Special Feature **Business Model** Powered by DX and S&T

As an innovative global healthcare company, we will contribute to healthcare transformation through excellent use of data and digital technology

The Daiichi Sankyo Group aims to further improve the value provided to patients by building a total care platform. With the platform, we offer an individual the best healthcare solutions by using our drug discovery platform and digital technologies during their lifetime.

Masahiko Ohtsuki

Director, Senior Executive Officer, Head of Digital Transformation Management Unit, CIO

The Daiichi Sankyo Group aims to provide new value to patients through the total care platform as shown in the figure on the right. We acknowledge that such a platform cannot be built only by pharmaceutical companies. For the platform, we need an ecosystem where various stakeholders collaborate, including individual patients, medical institutions, data providers providing real-world data*1, and IT companies providing the latest digital technologies.

We intend to collect data including individual's vital signs, behavioral information, medical checkup information, medical records, and real-world data, and analyze such data with the DX platform built by combining systems in and outside the Company. For the analyzation, medical and healthcare expertise as well as the latest digital technologies are required.

We also plan to build front-end services*2 so that the analyzed results can be fed back to individuals as visualized health information and therapy suggestions. In addition, when providing digital therapy, the front-end services allow users to access various information including their treatment data.

With these initiatives, we will provide new value to each individual, address difficulties that could not be solved with existing drugs, and meet expectations.

Going forward, we will introduce digital therapy as a new modality and also develop new medical services, including medical assistance from prevention to post-treatment.

*1: Services that customers use by directly accessing them

Creating Our New Value through DX

address difficulties that could not be solved with existing drugs, and meet expectations Digital therapy Medical support from Small molecule prevention to posttreatment Provision of new value LNP/mRNA for patient experiences through Gene/Cell therap digital technology New modalities Seamless and personalized medical support including **Total Care Platform** Pharmaceutical Eco system Data providers Individuals Data (vital, behavioral, R&D, Provision of information / advice Remote medical servicesAnalysis results / insight Technology Expertise (health and medical care) Front-end services Resource center Solution center Access to solutions

New Value

Services to consider each individual,

Pursue Total Care for Cancer Patients

Daiichi Sankyo is developing our business with the goal of "Global Pharma Innovator with Competitive Advantage in Oncology." As the first initiative to build a total care platform as mentioned earlier, we are focusing on "Total care for cancer patients." For cancer treatment, innovative cancer drugs are required. At the same time, it is important to continue the treatment with cancer drugs at an appropriate dosage and time period while sufficiently managing symptoms associated with cancer and side effects of cancer treatment.


In recent years, early supportive care and palliative care have attracted worldwide attention. As an initiative for optimal cancer treatment, we are taking an approach to make the most out of digital technologies so as to maximize the potential of drugs. Specifically, we started to develop digital therapeutics

that monitor the side effects of cancer treatment and symptoms associated with cancer, together with CureApp, Inc., which has experience with developing digital therapeutics covered by public health insurance.

With the app, we intend to manage symptoms associated with cancer and the side effects of cancer drugs. This will contribute to early intervention and prevention, and as a result, it is expected to increase efficacy in treatment, maintain and improve patients' QOL (Quality of Life), and improve the

Going forward, we will pursue total care that provides each cancer patient with optimal modality solutions including digital technology while as a medical partner.

Initiative of Optimized Cancer Treatment





DX That Supports Strategy Pillars for the 5-year Business Plan

We will facilitate data-driven management by integrating various data collected by departments including drug discovery, clinical development, production, and corporate units, and analyzing such data along with data from outside the company.

With new digital technology, we will transform the business process of the value chain and improve business efficiency so that we can spend more time on work that should be done by humans.

To advance digital transformation, we will enhance infrastructures such as IT, organizations, and human resources.

Create new value to provide through

data utilization Create new value by using integrated data from various sources like never before

Transformation of the value chain

Provide a high-level value quickly by transforming the process of drug discovery, development, production, and sales based on "Human × Digital Technology" rather than only "Human."























IT infrastructure **≐**‡

process



Enhance human resource base



Daiichi Sankyo Group Value Report 2021

Use of the DX platform and digital technologies (Al/IoT/Blockchain)

^{*2:} Clinical information in actual medical practice